PharmaLogic

PharmaLogic Holdings Corp. is a world-class contract development and manufacturing organization (CDMO) specializing in radiopharmaceutical production and distribution. The company focuses on novel diagnostic imaging and therapeutic radiopharmaceuticals for the treatment of cancers and other malignancies. PharmaLogic's expertise spans drug development from discovery through manufacturing and commercialization. The company operates an established network of radiopharmacies and has been expanding its cyclotron network and CDMO footprint to increase access to the latest radiopharmaceutical technology across the US.

PharmaLogic has been actively expanding its production capabilities with the opening of new state-of-the-art radiopharmaceutical production and research facilities. In April 2024, the company launched a new facility in Cincinnati, Ohio, equipped to expand current production and focus on research and development of novel compounds. This was followed by the opening of another facility in the Bronx, New York, in May 2024. The Bronx facility, acquired in 2022 and extensively renovated, is designed to ensure a consistent supply of critical radiopharmaceuticals for the community and serve as a launchpad for new radio-ligand diagnostic and therapeutic drugs.

Key customers and partnerships

PharmaLogic has established partnerships with several pharmaceutical companies and healthcare providers. In March 2024, the company expanded its manufacturing agreement with Ratio Therapeutics Inc., a pharmaceutical company developing radiopharmaceuticals for cancer treatment and monitoring. This collaboration aims to accelerate the development and commercialization of Ratio's pipeline of next-generation radiotherapies, particularly their fibroblast activation protein-alpha (FAP)-targeted radiotherapeutic candidate.

In May 2023, PharmaLogic announced a collaboration with Nusano, Inc., a company focused on reshaping the production of cancer-fighting radioisotopes. This partnership aims to advance the development of radiopharmaceuticals for diagnostic and therapeutic applications, leveraging the close proximity of their facilities in the greater Salt Lake area.

In March 2024, PharmaLogic partnered with Intermountain Health to build a new cyclotron facility in Murray, Utah. This facility will produce radiopharmaceuticals used to diagnose certain medical conditions and treat various types of cancer, ensuring more of these products are available locally for a wide range of imaging applications.